Chiara Pilotto1,2, Ismail Beshlawi3, Adam Thomas4, Richard G Grundy3. 1. Children's Brain Tumour Research Centre, University of Nottingham, Nottingham, UK. Pilotto.chiara@spes.uniud.it. 2. Department of Sperimental and Clinical Medical Science, DISM, University of Udine, Udine, Italy. Pilotto.chiara@spes.uniud.it. 3. Children's Brain Tumour Research Centre, University of Nottingham, Nottingham, UK. 4. Department of Neuroradiology, Nottingham University Hospitals NHS Trust, Nottingham, UK.
Abstract
BACKGROUND: Bevacizumab (BVZ) is a vascular endothelial growth factor inhibitor that has been widely accepted since its introduction into the cancer pharmacopoeia. Anecdotal reports suggested improvements in vision in children with visual pathway glioma. CASE PRESENTATION: We report a boy with visual pathway glioma whose vision had deteriorated significantly on vincristine and carboplatin, to the point that he was registered blind. Following bevacizumab therapy, there was a dramatic improvement in vision with reduction in tumour volume. However, following 20 doses of BVZ given over 19 months, he developed a significant cerebrovascular stenosis. CONCLUSION: The BVZ-induced cerebrovascular diseases in children are extremely rare but potentially serious. Importantly, stenosis has not been previously described in literature.
BACKGROUND:Bevacizumab (BVZ) is a vascular endothelial growth factor inhibitor that has been widely accepted since its introduction into the cancer pharmacopoeia. Anecdotal reports suggested improvements in vision in children with visual pathway glioma. CASE PRESENTATION: We report a boy with visual pathway glioma whose vision had deteriorated significantly on vincristine and carboplatin, to the point that he was registered blind. Following bevacizumab therapy, there was a dramatic improvement in vision with reduction in tumour volume. However, following 20 doses of BVZ given over 19 months, he developed a significant cerebrovascular stenosis. CONCLUSION: The BVZ-induced cerebrovascular diseases in children are extremely rare but potentially serious. Importantly, stenosis has not been previously described in literature.
Authors: Eugene I Hwang; Regina I Jakacki; Michael J Fisher; Lindsay B Kilburn; Marianna Horn; Gilbert Vezina; Brian R Rood; Roger J Packer Journal: Pediatr Blood Cancer Date: 2012-09-13 Impact factor: 3.167
Authors: Raymond C S Seet; Alejandro A Rabinstein; Paul E Lindell; Joon H Uhm; Eelco F Wijdicks Journal: Neurocrit Care Date: 2011-12 Impact factor: 3.210
Authors: Julia L Glade Bender; Peter C Adamson; Joel M Reid; Lu Xu; Sylvain Baruchel; Yuval Shaked; Robert S Kerbel; Erin M Cooney-Qualter; Diana Stempak; Helen X Chen; Marvin D Nelson; Mark D Krailo; Ashish M Ingle; Susan M Blaney; Jessica J Kandel; Darrell J Yamashiro Journal: J Clin Oncol Date: 2008-01-20 Impact factor: 44.544
Authors: Jason Fangusaro; Sridharan Gururangan; Tina Young Poussaint; Roger E McLendon; Arzu Onar-Thomas; Katherine E Warren; Shengjie Wu; Roger J Packer; Anu Banerjee; Richard J Gilbertson; Regina Jakacki; Amar Gajjar; Stewart Goldman; Ian F Pollack; Henry S Friedman; James M Boyett; Larry E Kun; Maryam Fouladi Journal: Cancer Date: 2013-09-19 Impact factor: 6.860
Authors: Henry S Friedman; Michael D Prados; Patrick Y Wen; Tom Mikkelsen; David Schiff; Lauren E Abrey; W K Alfred Yung; Nina Paleologos; Martin K Nicholas; Randy Jensen; James Vredenburgh; Jane Huang; Maoxia Zheng; Timothy Cloughesy Journal: J Clin Oncol Date: 2009-08-31 Impact factor: 44.544